170 related articles for article (PubMed ID: 25910065)
21. Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States.
Sharma P; Falk GW; Bhor M; Ozbay AB; Latremouille-Viau D; Guérin A; Shi S; Elvekrog MM; Limburg P
Medicine (Baltimore); 2023 Mar; 102(12):e33072. PubMed ID: 36961193
[TBL] [Abstract][Full Text] [Related]
22. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
23. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
24. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
25. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
[TBL] [Abstract][Full Text] [Related]
26. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
27. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
28. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
29. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
30. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
[TBL] [Abstract][Full Text] [Related]
31. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
[TBL] [Abstract][Full Text] [Related]
32. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
[TBL] [Abstract][Full Text] [Related]
33. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
34. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
35. Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.
Tsoi EH; Mahindra P; Cameron G; Williams R; Norris R; Desmond PV; Raftopoulos S; Pavey D; Rattan A; Hourigan LF; Lee R; Bourke MJ; Sidhu N; Singh R; Chan A; Krishnamurthi S; Taylor ACF
Gastrointest Endosc; 2021 Nov; 94(5):902-908. PubMed ID: 34033852
[TBL] [Abstract][Full Text] [Related]
36. The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study.
Phillips R; Januszewicz W; Pilonis ND; O'Donovan M; Sawas T; Katzka DA; Fitzgerald RC; di Pietro M
Gastrointest Endosc; 2021 Aug; 94(2):263-270.e2. PubMed ID: 33548281
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of Barrett's high-grade dysplasia.
Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
[TBL] [Abstract][Full Text] [Related]
38. Adherence to clinical guidelines for Barrett's esophagus.
Holmberg D; Ness-Jensen E; Mattsson F; Lagergren J
Scand J Gastroenterol; 2019 Aug; 54(8):945-952. PubMed ID: 31314608
[No Abstract] [Full Text] [Related]
39. Risk of progression of Barrett's esophagus in patients with cirrhosis.
Apfel T; Lopez R; Sanaka MR; Thota PN
World J Gastroenterol; 2017 May; 23(18):3287-3294. PubMed ID: 28566888
[TBL] [Abstract][Full Text] [Related]
40. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
